摘要
目的探讨Ki67检测在乳腺癌新辅助化疗临床疗效判断中的作用。方法81例乳腺癌患者给予3个周期化疗后手术。化疗方案：环磷酰胺600me,／m2，第1天；盐酸阿霉素100mg／m2，第1天；5-氟尿嘧啶600mg／m2，第1天；21d为1个周期。用免疫组化方法检测患者新辅助化疗前后Ki67表达情况，并分析肿瘤组织化疗后反应。结果Ki67在新辅助化疗前56例高表达，25例低表达，高表达率为69．1％。新辅助化疗后18例高表达，63例（77．8％）低表达，差异有统计学意义（x2=35．92，P〈0．05）。新辅助化疗后Ki67高表达18例中，化疗有效5例，无效13例；63例低表达中有效43例，无效20例，差异有统计学意义（P〈0．05）。新辅助化疗前后Ki67指数变化明显者化疗反应明显。结论Ki67检测可以指导新辅助化疗用药，是一种判断化疗疗效的分子生物学指标。
Objective To study the changes of Ki67 index in breast cancer tissue and to analyze the effect and the significance in neoadjuvant chemotherapy. Methods The expression of the Ki67 before and after neoadjuvant chemotherapy in 81 cases breast cancer patients was examined. The pathological reaction of breast cancer tissues after neoadjuvant chemotherapy was studied. Results The expression of Ki67 had significant changes after neoadjuvant chemotherapy [ high expression：IS cases： 56 cases, low expression： 63 cases： 25 cases, P 〈 0. 05 ]. Patients with significant Ki67changes showed good outcomes with neoadjuvant chemotherapy. Conclusion The index of Ki67 can be a guide for drug use of neoadjuvant chemotherapy and it is a strong prognostic molecular marker for judging the curative effect of chemotherapy.
出处
《中国医药》
2012年第2期184-185,共2页
China Medicine
关键词
乳腺肿瘤
新辅助化疗
Breast neoplasms
Neoadjuvant chemotherapy
